Roche's Alecensa latest beneficiary of faster China drug approvals
Chinese regulators are speeding up drug approvals, with Roche's Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.
from Reuters: Health News https://reut.rs/2vXIPG6
http://bit.ly/2zwRqiM